AzTrials
AzTrials

Respiratory InsufficiencyNCT07484802

Vela Generation II: Usability and Performance of a Non-Invasive Ventilation Mask.

A study testing NIV interface with airway washout in people with Respiratory Insufficiency and Respiratory Failure, run by Fisher and Paykel Healthcare.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Study Overview The goal of this clinical trial is to learn whether an improved non invasive ventilation mask with airway washout can reduce how often people need to breathe and perform as well as standard NIV masks when used with different ventilators, in people receiving NIV therapy for respiratory distress or… Read more about this study

Who is it for?
Ages 21 years and older
What is being tested?
NIV interface with airway washout
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
No sites listed yet
Study dates
1 Jul 2026to 31 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults that are stable on prescribed NIV
  • Able to receive NIV therapy on a sub-nasal mask
  • Are 21 years old or older

Who cannot join

  • Contraindicated for NIV
  • NIV is likely to fail and/or intubation be required, at the doctor's discretion
  • CPAP or bilevel pressure of ≥ 30 cmH2O required
  • Do not fit the investigation mask or the standard mask
  • Pregnancy (tested under standard care)
  • Unable to tolerate NIV for the duration of the investigation
  • Unable to understand the consent process

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Senior clinical research scientist, doctorate contact

+64210624848

lotte.vandenheuij@fphcare.co.nz

About this study

Official title: Vela Generation II: Usability and Performance of a Non-Invasive Ventilation Mask. A Prospective Self-Controlled Study.

Study Overview The goal of this clinical trial is to learn whether an improved non invasive ventilation mask with airway washout can reduce how often people need to breathe and perform as well as standard NIV masks when used with different ventilators, in people receiving NIV therapy for respiratory distress or respiratory insufficiency.

The main question(s) it aims to answer are:

Read more
  • Does the new mask reduce breathing rate compared with a standard NIV mask?
  • Does the ventilator perform as expected when used with the new mask, including pressure delivery and leak?
  • Do clinicians and participants find the new mask fits and functions well?

Three iterations of the new mask (vented, non-vented, dual limb) will be compared to standard of care to see if the mask reduces the need to breathe and performs consistently across ventilators compared with usual NIV masks.

________________________________________ What Participants Will Do Participants will wear two different NIV masks, each for one hour, during a single study session lasting approximately 2.5 hours.

Participants will be asked to:

  • Wear a small, stick on carbon dioxide (CO₂) sensor on the skin.
  • Use their usual NIV mask for one hour while ventilator data are collected.
  • Switch to the investigational mask for one hour while ventilator data are collected.
  • Choose whether to return to their original mask or remain on the investigational mask after the study period.
  • Caregiver opinion on the mask will be collected.

Participants may also choose (optional):

  • To have three small blood samples taken (These samples are optional, and participants can still take part in the study if they decline them.)
  • One when they agree to take part in the study
  • One when the investigational mask is fitted
  • One after wearing the investigational mask for one hour
  • To provide feedback on how the two masks felt and performed.

During the study, researchers will collect data from the ventilator, including:

  • Breathing rate and depth
  • NIV pressure settings
  • Amount of air leak Research staff will also complete a short form assessing how well the mask fit and functioned. Participants will remain in the study until the investigational mask is removed.
Read the detailed description

The investigational masks perform as the commercially available comparators delivering the prescibed NIV, with the potential benefit of upper airway and instrumental dead space washout. This should improve RR by approximately 3 BPM. This study is to establish the investigation mask has similar usability as the comparator with improved efficacy, potentially reducing RR. The knowledge gained during this clinical investigation may provide further clinical benefits to patients with respiratory failure.

Non-invasive ventilation (NIV) is a method of delivering respiratory support without using an endotracheal tube. It's a first-line treatment for specific conditions like COPD exacerbations and acute cardiogenic pulmonary edema. NIV aims to improve gas exchange, reduce work of breathing, avoid intubation, and reduce complications.

For patients with COPD exacerbations and acute cardiogenic pulmonary edema NIV is a first line therapy. NIV is also considered for other conditions like acute respiratory failure due to asthma exacerbation and in immunocompromised individuals with acute respiratory insufficiency. Additionally, it can be used in post-operative respiratory failure, for difficult weaning, and to prevent post-extubation failure.

NIV has been shown to result in overall better outcomes than mechanical ventilation with reduced mortality and morbidity, fewer ICU acquired infections improved lung function and shorter ICU stays. The severity of the respiratory insufficiency influences the likelihood of successful NIV. One factor associated with respiratory sufficiency is respiratory dead space. This is the volume in the respiratory apparatus that does not partake in gas exchange and in the ventilated patient includes the volume in the equipment, the conductive airways and pathological respiratory tissue. A high dead-space fraction early in the course of the illness is association with increased risk of death.9 Particularly in patients that have a small tidal volume and high respiratory rate, or patients with an increased physiological dead space due to lung disease, a change in instrumental dead space can have a large impact on alveolar minute ventilation. Improved alveolar ventilation can improve CO2 elimination and help to reduce respiratory acidosis as well as improve oxygen delivery.10, 11 This can consequently reduce the respiratory effort required by the patient. 12 If the physician instead chooses to keep arterial CO2 concentration (PaCO2) constant, a reduction of instrumental dead space will allow a reduction of tidal volume, plateau pressure, driving pressure, or a reduction of the respiratory rate and thus a reduction in work of breathing.

NIV with washout improves ventilation compared to conventional NIV by reducing expired air in each breath. This may result in faster normalization of ventilatory gases and a reduced work of breathing, the patient may improve more rapidly as alveolar ventilation is improved. Or, allow for a reduction in pressure for similar ventilatory benefits, potentially improving NIV tolerance and therapy adherence. In stable COPD patients, NIV with Airway Washout resulted in a significant reduction in minute ventilation compared to conventional NIV. This was approximately 19% lower with OptiNIV compared to conventional NIV.15 In this study minute ventilation will be calculated from the RR and Vt retrieved from the ventilator to asses improvement in ventilation over the study period, this self-control study aims to establish efficacy of airway washout and whether the generation 2 design changes do not impact usability. When airway washout becomes more widely available it may improve NIV therapy efficacy by improving ventilation or reducing the pressure needed for a similar level of ventilatory support.

Being tested
NIV interface with airway washout
Keywords
Airway washout, Fisher and Paykel healthcare, optiNIV, vela gen 2
Medical subject headings
Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NIV interface with airway washoutOther

    This is a new design of the OptiNIV mask with airway washout that is commercially available.

Study groups in NCT07484802
Study groupRoleWhat they receive
Investigational MaskExperimentalThis is the arm with the second generation OptiNIV mask with airway washout. this new mask function very much like the commercially available OptiNIV mask but for a wider population as the maximum pressure is 40 not 30 cmH20 and on a wider variety of ventilators now also having a dual limb solution.
Receives: Other: NIV interface with airway washout
Standard careNo interventionThe standard of care mask the participant is on when they are recruited. this is the comparator.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. respiratory rate

    A reduction in respiratory rate of 3 bpm. The RR will be taken off the ventilator as a continuous measure out of the coms protocol we will download. Point measures will also be taken in the event the vent data is corrupted. RR at 10 min intervals will be noted down in the CRF.

    We expect a normal improvement in ventilation over time but are expecting a steeper improvement in RR in the intervention arm of 3 BPM.

    Measured: 1 hour per arm of continuous ventilator data.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Mar 2026
  2. Study start1 Jul 2026 (estimated)
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Non-randomised
Intervention model
Sequential
Model description
prospective, non-randomized self controlled study. Comparing within participant outcomes between standard of care and the novel mask with airway washout
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07484802
Sponsor's protocol ID
CIA-379
Status last verified
Mar 2026
First submitted
16 Mar 2026
Last updated
20 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing NIV interface with airway washout in people with Respiratory Insufficiency and Respiratory Failure, run by Fisher and Paykel Healthcare.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Senior clinical research scientist, doctorate (+64210624848, lotte.vandenheuij@fphcare.co.nz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

respiratory rate (time frame: 1 hour per arm of continuous ventilator data.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in